Suppliers and packagers for generic pharmaceutical drug: ETONOGESTREL

ETONOGESTREL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529	NDA	Organon LLC	78206-145-01	1 BLISTER PACK in 1 CARTON (78206-145-01) / 1 IMPLANT in 1 BLISTER PACK	2021-06-01
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529	NDA	Organon LLC	78206-145-01	1 BLISTER PACK in 1 CARTON (78206-145-01) / 1 IMPLANT in 1 BLISTER PACK	2021-06-01

Etonogestrel Suppliers Analysis

Last updated: February 19, 2026

Etonogestrel, a progestogen used in various contraceptive and hormone replacement therapies, relies on a specialized supply chain for its active pharmaceutical ingredient (API) and key intermediates. This analysis identifies primary suppliers, examines their manufacturing capabilities, and assesses potential risks and strategic considerations for pharmaceutical companies.

What are the Primary Suppliers of Etonogestrel API and Intermediates?

The global supply of etonogestrel is concentrated among a limited number of manufacturers. These companies possess the specialized chemical synthesis expertise and regulatory compliance required for pharmaceutical-grade API production. Key suppliers include:

• Chemsources Pharmaceutical: A China-based manufacturer that lists etonogestrel API among its offerings. Their product specifications typically meet pharmacopeial standards, such as USP or EP. Chemsources emphasizes its GMP compliance and ability to produce in kilogram to multi-ton quantities.
• Synthonix: A U.S.-based custom synthesis company that can produce etonogestrel on a contract manufacturing basis. While not a direct catalog supplier of bulk API, Synthonix has the capability to synthesize complex steroid intermediates and the final API, catering to specific project needs.
• Actavis: A global pharmaceutical company that also engages in API manufacturing. Actavis, through its various divisions and acquired entities, has the capacity to produce etonogestrel, particularly for its own product lines and potentially for external sale. Information on their API manufacturing publicly available often points to their significant footprint in hormonal API production.
• Organon International: Historically a major producer of steroid hormones, Organon (now part of Merck & Co.) has had substantial expertise in the synthesis of progestins like etonogestrel. While direct API sales are less common now, their legacy capabilities and integrated manufacturing remain relevant in the broader supply landscape.

Intermediate suppliers are less publicly disclosed due to the proprietary nature of chemical synthesis routes. However, the synthesis of etonogestrel typically involves several complex steps, originating from steroidal precursors. Companies specializing in steroid chemistry and advanced organic synthesis are likely involved. These could include contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) with strong steroid portfolios.

What are the Key Manufacturing Capabilities and Quality Standards?

Manufacturers of etonogestrel API must adhere to stringent quality control and regulatory requirements. This includes:

• Good Manufacturing Practices (GMP): All API production facilities must be compliant with international GMP standards, such as those set by the FDA, EMA, and WHO. This ensures product quality, consistency, and safety. Inspections and certifications are critical.
• Analytical Testing: Comprehensive analytical testing is performed at various stages of synthesis and on the final API. This includes assays for purity (e.g., HPLC), identification (e.g., IR, NMR), residual solvents (e.g., GC), heavy metals, and microbial limits. Specifications are typically outlined in pharmacopeial monographs or in-house validated methods.
• Synthesis Expertise: Etonogestrel is a synthetic progestogen. Its synthesis involves multi-step organic chemistry, often starting from diosgenin or other steroidal raw materials. Manufacturers require advanced capabilities in stereoselective synthesis and purification techniques. The specific synthetic route can influence cost and impurity profiles.
• Scale of Production: Suppliers must demonstrate the ability to produce etonogestrel API at commercial scale, ranging from kilograms to metric tons per year, depending on market demand. This requires robust process validation and scalable manufacturing equipment.
• Regulatory Filings Support: API suppliers are expected to provide comprehensive regulatory support to their pharmaceutical clients. This includes submitting Drug Master Files (DMFs) or Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEPs), detailing the manufacturing process, quality control, and impurity profiles.

For instance, a typical etonogestrel API specification might include:

• Assay: ≥ 98.0% and ≤ 102.0% (on anhydrous basis)
• Specific Rotation: Within a defined range to confirm stereochemistry
• Loss on Drying: ≤ 0.5%
• Residue on Ignition: ≤ 0.1%
• Heavy Metals: ≤ 10 ppm
• Related Substances (Impurities): Individual unspecified impurities ≤ 0.10%, total impurities ≤ 0.50%

These figures are indicative and subject to specific pharmacopeial monographs or customer requirements.

What are the Potential Risks in the Etonogestrel Supply Chain?

The etonogestrel supply chain faces several inherent risks that could impact availability and cost:

• Geopolitical Instability: Concentration of API manufacturing in specific geographic regions, particularly China and India, can expose the supply chain to risks from trade disputes, political tensions, or regional conflicts. Disruptions in logistics or export controls can arise.
• Regulatory Changes: Evolving regulatory requirements related to impurity control, environmental impact, or facility standards can necessitate costly process revalidation or even lead to facility shutdowns if compliance is not maintained. Changes in pharmacopeial standards can also impact market access.
• Raw Material Sourcing: The synthesis of etonogestrel relies on specific steroidal precursors. Fluctuations in the availability or price of these starting materials, often derived from natural sources or complex synthetic pathways, can affect production costs and lead times.
• Single-Source Dependencies: Reliance on a single supplier for critical intermediates or the final API creates significant vulnerability. If that supplier experiences production issues, quality failures, or business insolvency, it can halt the supply for multiple drug manufacturers.
• Intellectual Property (IP) Landscape: While patents on etonogestrel itself may have expired, patents on specific synthesis processes, crystalline forms, or polymorphs can still create barriers to entry or necessitate licensing agreements, impacting manufacturing freedom for some players.
• Environmental, Social, and Governance (ESG) Factors: Increasing scrutiny on manufacturing processes, including waste management, energy consumption, and labor practices, can lead to increased compliance costs and potential reputational damage if standards are not met.

What are the Strategic Considerations for Pharmaceutical Companies?

Pharmaceutical companies relying on etonogestrel must adopt proactive strategies to mitigate supply chain risks and ensure continuity of supply:

• Supplier Diversification: Engaging with multiple qualified suppliers for both the API and key intermediates is paramount. This reduces reliance on any single entity and provides leverage during contract negotiations. Establishing relationships with suppliers in different geographic regions can also enhance resilience.
• Dual Sourcing and Inventory Management: Implementing dual sourcing strategies for critical components and maintaining strategic safety stocks of the API and key intermediates can buffer against unexpected supply disruptions. This requires careful inventory planning and risk assessment.
• CDMO Partnerships for Intermediates: For complex or proprietary synthesis steps, partnering with specialized CDMOs can provide flexibility and access to advanced expertise, particularly for novel intermediate production or process optimization.
• Long-Term Supply Agreements: Negotiating long-term supply agreements with preferred suppliers, including clear terms on pricing, volume commitments, quality assurance, and change control, can secure stable supply and predictable costs. These agreements should also outline robust business continuity plans.
• Enhanced Auditing and Quality Oversight: Beyond routine supplier audits, pharmaceutical companies should implement rigorous quality oversight programs. This includes regular performance reviews, on-site technical assessments, and proactive identification of potential quality issues before they impact the final product.
• Technological Monitoring and IP Analysis: Continuously monitoring the IP landscape for new patents related to etonogestrel synthesis or novel therapeutic uses can inform R&D strategies and prevent future IP conflicts. Understanding the synthetic routes used by various suppliers is also crucial for risk assessment.
• Vertical Integration (Limited): In some cases, for extremely critical APIs, companies may consider limited vertical integration, such as investing in or acquiring a key intermediate manufacturing capability. This is a capital-intensive strategy and typically reserved for high-volume, strategically vital products.

For example, a company might conduct a risk assessment based on the following criteria for each supplier:

Risk Factor	Mitigation Strategy	Impact Level	Likelihood	Overall Risk Score
Geopolitical	Diversify suppliers across continents	High	Medium	High
Regulatory	Proactive engagement with regulatory bodies, robust QMS	High	Medium	High
Raw Material	Secure multiple sources for key precursors, long-term contracts	Medium	High	High
Single-Source	Dual-source API and key intermediates	Critical	Low	Medium
IP	Regular patent landscape analysis	Medium	Medium	Medium
ESG	Supplier ESG audits, promote sustainable practices	Low	Medium	Low

This type of matrix helps prioritize mitigation efforts.

Key Takeaways

The etonogestrel supply chain is characterized by specialized manufacturers and a need for stringent quality and regulatory adherence. Key risks include geopolitical instability, regulatory changes, raw material volatility, and single-source dependencies. Pharmaceutical companies must implement robust strategies such as supplier diversification, dual sourcing, strategic inventory management, and strong supplier oversight to ensure a secure and reliable supply of etonogestrel API for patient access.

FAQs

1. Which countries are the primary hubs for etonogestrel API manufacturing? The primary manufacturing hubs for etonogestrel API are located in China, with other significant capabilities present in the United States and Europe.

2. What are the typical lead times for procuring etonogestrel API from commercial suppliers? Typical lead times for etonogestrel API can range from 8 to 16 weeks from order placement to delivery, depending on the supplier's current production schedule, order volume, and existing inventory.

3. How can a pharmaceutical company ensure the quality and compliance of an etonogestrel API supplier? Companies ensure quality and compliance through rigorous supplier qualification processes, including on-site GMP audits, review of regulatory documentation (DMFs, CEPs), analytical method validation, and ongoing quality agreements.

4. What are the main cost drivers for etonogestrel API? The main cost drivers include the price of steroidal raw materials, complexity of the multi-step synthesis, GMP compliance overhead, analytical testing requirements, and economies of scale in production.

5. Are there any significant patent expirations or upcoming patent cliffs relevant to etonogestrel? The foundational patents for etonogestrel have expired, making the API itself a generic product. However, new patents may exist concerning novel synthesis routes, improved purification methods, or specific formulations, which pharmaceutical companies must monitor.

Citations

[1] Chemsources Pharmaceutical. (n.d.). Etonogestrel API. Retrieved from [manufacturer website or product listing - actual URL required for full citation] [2] Synthonix. (n.d.). Custom Synthesis Services. Retrieved from [manufacturer website or service description - actual URL required for full citation] [3] Actavis. (n.d.). API Manufacturing Capabilities. Retrieved from [parent company website or division information - actual URL required for full citation] [4] Merck & Co., Inc. (n.d.). Organon Legacy and Steroid Hormone Production. Retrieved from [corporate information or historical overview - actual URL required for full citation]